Search Results - Martin Lefkowitz

Refine Results
  1. 1
    Atypical apocrine adenosis of the breast: A clinicopathologic study of 37 patients with 8.7-year follow-up

    Atypical apocrine adenosis of the breast: A clinicopathologic study of 37 patients with 8.7-year follow-up by Jeffrey D. Seidman, Mark A. Ashton, Martin Lefkowitz

    Published 1996
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  2. 2
    Aggressive angiomyxoma: A clinicopathologic study of 29 female patients

    Aggressive angiomyxoma: A clinicopathologic study of 29 female patients by John F. Fetsch, William B. Laskin, Martin Lefkowitz, Lars‐Gunnar Kindblom, Jeanne M. Meis‐Kindblom

    Published 1996
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    The Effects of Aldosterone Synthase Inhibition on Aldosterone and Cortisol in Patients With Hypertension: A Phase II, Randomized, Double‐Blind, Placebo‐Controlled, Multicenter Study

    The Effects of Aldosterone Synthase Inhibition on Aldosterone and Cortisol in Patients With Hypertension: A Phase II, Randomized, Double‐Blind, Placebo‐Controlled, Multicenter Stud... by Karl Andersen, Daniel Hartman, Thomas Peppard, David Hermann, Peter Van Ess, Martin Lefkowitz, Angelo J. Trapani

    Published 2012
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  4. 4
    A randomized, double‐blind, placebo‐controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation

    A randomized, double‐blind, placebo‐controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation by J. Novick, Philip B. Miner, Richard A. Krause, Kathie Glebas, H Bliesath, Gregory Ligozio, P. Rüegg, Martin Lefkowitz

    Published 2002
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  5. 5
    Effects of a Novel Aldosterone Synthase Inhibitor for Treatment of Primary Hypertension

    Effects of a Novel Aldosterone Synthase Inhibitor for Treatment of Primary Hypertension by David A. Calhoun, William B. White, Henry Krum, Weinong Guo, Georgina Bermann, Angelo J. Trapani, Martin Lefkowitz, Joël Ménard

    Published 2011
    Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized controlled trial to compare the clinical outcome effects of first-line combination therapies in hypertension.

    Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial: the first randomized contro... by Kenneth Jamerson, George L. Bakris, C. C. Wun, Björn Dahlöf, Martin Lefkowitz, S Manfreda, Bertram Pitt, Eric J. Velazquez, Michael A. Weber

    Published 2004
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  7. 7
    Inhibition of Interleukin-1β by Canakinumab and Cardiovascular Outcomes in Patients With Chronic Kidney Disease

    Inhibition of Interleukin-1β by Canakinumab and Cardiovascular Outcomes in Patients With Chronic Kidney Disease by Paul M. Ridker, Jean MacFadyen, Robert J. Glynn, Wolfgang Köenig, Peter Libby, Giulia Renda, Martin Lefkowitz, Tom Thurén, Jan H. Cornel

    Published 2018
    Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    Efficacy and Safety of LCZ696, a First-in-Class Angiotensin Receptor Neprilysin Inhibitor, in Asian Patients With Hypertension

    Efficacy and Safety of LCZ696, a First-in-Class Angiotensin Receptor Neprilysin Inhibitor, in Asian Patients With Hypertension by Kazuomi Kario, Ningling Sun, Fu‐Tien Chiang, Ouppatham Supasyndh, Sang Hong Baek, Akiko Inubushi-Molessa, Ying Zhang, Hiromi Gotou, Martin Lefkowitz, Jack Zhang

    Published 2014
    Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    Estimating the Long-Term Treatment Benefits of Sacubitril–Valsartan

    Estimating the Long-Term Treatment Benefits of Sacubitril–Valsartan by Brian Claggett, Milton Packer, John J.V. McMurray, Karl Swedberg, Jean L. Rouleau, Michael R. Zile, Pardeep S. Jhund, Martin Lefkowitz, Victor Shi, Scott D. Solomon

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial

    Factors Associated With Noncompletion During the Run-In Period Before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial by Akshay S. Desai, Scott D. Solomon, Brian Claggett, John J.V. McMurray, Jean L. Rouleau, Karl Swedberg, Michael R. Zile, Martin Lefkowitz, Victor Shi, Milton Packer

    Published 2016
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    Efficacy of Sacubitril/Valsartan Relative to a Prior Decompensation

    Efficacy of Sacubitril/Valsartan Relative to a Prior Decompensation by Scott D. Solomon, Brian Claggett, Milton Packer, Akshay Desai, Michael R. Zile, Karl Swedberg, Jean L. Rouleau, Victor Shi, Martin Lefkowitz, John J.V. McMurray

    Published 2016
    Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    A putative placebo analysis of the effects of sacubitril/valsartan in heart failure across the full range of ejection fraction

    A putative placebo analysis of the effects of sacubitril/valsartan in heart failure across the full range of ejection fraction by Muthiah Vaduganathan, Pardeep S. Jhund, Brian Claggett, Milton Packer, J Widimský, Petar Seferović, Adel R. Rizkala, Martin Lefkowitz, Victor Shi, John J.V. McMurray, Scott D. Solomon

    Published 2020
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    Exceptional early blood pressure control rates: The ACCOMPLISH trial

    Exceptional early blood pressure control rates: The ACCOMPLISH trial by Kenneth Jamerson, George L. Bakris, Björn Dahlöf, Bertram Pitt, Eric J. Velazquez, Jitendra Gupte, Martin Lefkowitz, Allen Hester, Victor Shi, Sverre E. Kjeldsen, William C. Cushman, Vasilios Papademetriou, Michael A. Weber, Kenneth Jamerson, George L. Bakris, Björn Dahlöf, Bertram Pitt, Eric J. Velazquez, Jitendra Gupte, Martin Lefkowitz, Allen Hester, Victor Shi, Sverre E. Kjeldsen, William C. Cushman, Vasilios Papademetriou, Michael A. Weber

    Published 2007
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, <scp>LCZ696</scp>, in patients with heart failure with preserved ejection fraction: an analysis of the <scp>PARAMOUNT</scp> trial

    Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, <scp>LCZ696</scp>, in patients with heart failure with preserved e... by Pardeep S. Jhund, Brian Claggett, Milton Packer, Michael R. Zile, Adriaan A. Voors, Burkert Pieske, Martin Lefkowitz, Victor Shi, Toni Bransford, John J.V. McMurray, Scott D. Solomon

    Published 2014
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    Baseline characteristics and treatment of patients in Prospective comparison of <scp>ARNI</scp> with <scp>ACEI</scp> to Determine Impact on Global Mortality and morbidity in Heart Failure trial (<scp>PARADIGM‐HF</scp>)

    Baseline characteristics and treatment of patients in Prospective comparison of <scp>ARNI</scp> with <scp>ACEI</scp> to Determine Impact on Global Mortality and morbidity in Heart... by John J.V. McMurray, Milton Packer, Akshay S. Desai, Jianjian Gong, Martin Lefkowitz, Adel R. Rizkala, Jean L. Rouleau, Victor Shi, Scott D. Solomon, Karl Swedberg, Michael R. Zile

    Published 2014
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin‐converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM‐HF)

    Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin‐converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and... by John J.V. McMurray, Milton Packer, Akshay S. Desai, Jim Gong, Martin Lefkowitz, Adel R. Rizkala, Jean L. Rouleau, Victor Shi, Scott D. Solomon, Karl Swedberg, Michael R. Zile

    Published 2013
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure

    Angiotensin–Neprilysin Inhibition versus Enalapril in Heart Failure by John J.V. McMurray, Milton Packer, Akshay S. Desai, Jianjian Gong, Martin Lefkowitz, Adel R. Rizkala, Jean L. Rouleau, Victor Shi, Scott D. Solomon, Karl Swedberg, Michael R. Zile

    Published 2014
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  18. 18
    Renal effects of the angiotensin receptor neprilysin inhibitor <scp>LCZ696</scp> in patients with heart failure and preserved ejection fraction

    Renal effects of the angiotensin receptor neprilysin inhibitor <scp>LCZ696</scp> in patients with heart failure and preserved ejection fraction by Adriaan A. Voors, Mauro Gori, Licette C.Y. Liu, Brian Claggett, Michael R. Zile, Burkert Pieske, John J.V. McMurray, Milton Packer, Victor Shi, Martin Lefkowitz, Scott D. Solomon

    Published 2015
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction

    Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction by Michael R. Zile, Pardeep S. Jhund, Catalin F. Baicu, Brian Claggett, Burkert Pieske, Adriaan A. Voors, Margaret F. Prescott, Victor Shi, Martin Lefkowitz, John J.V. McMurray, Scott D. Solomon

    Published 2016
    Get full text
    Artigo
    Save to List
    Saved in:
  20. 20
    Effects of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFrEF

    Effects of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFrEF by Michael R. Zile, Eileen O’Meara, Brian Claggett, Margaret F. Prescott, Scott D. Solomon, Karl Swedberg, Milton Packer, John J.V. McMurray, Victor Shi, Martin Lefkowitz, Jean L. Rouleau

    Published 2019
    Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: